Early Clinical Effects of Novel Partial D3/D2 Agonist Cariprazine in Schizophrenia Patients With Predominantly Negative Symptoms (Open-Label, Non-controlled Study)

Early Clinical Effects of Novel Partial D3/D2 Agonist Cariprazine in Schizophrenia Patients With Predominantly Negative Symptoms (Open-Label, Non-controlled Study)

BackgroundBecause of limited efficacy of antipsychotics against negative symptoms in schizophrenia new drugs with wider spectrums of clinical efficacy are very desirable. The newer 3rd generation antipsychotic cariprazine presents the unique mode of action acting as partial agonist predominantly for...

Full description

Bibliographic Details
Main Authors: Stanislav V. Ivanov, Anatoly B. Smulevich, Evgeniya I. Voronova, Kausar K. Yakhin, Tangyul Z. Beybalaeva, Alena A. Katok
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Psychiatry
Subjects:
schizophrenia
negative symptoms
pharmacotherapy
clinical effects
cariprazine
Online Access:https://www.frontiersin.org/articles/10.3389/fpsyt.2021.770592/full

Internet

https://www.frontiersin.org/articles/10.3389/fpsyt.2021.770592/full

Similar Items